Compare Jabil Inc (JBL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Summit Therapeutics Inc — how do they compare? Jabil Inc trades at $306.28 (market cap $31.35B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Jabil Inc is far larger — about 2.3× Summit Therapeutics Inc's market cap, and Jabil Inc pays a 0.11% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Summit Therapeutics Inc for 16 Days on average.
| JBL | SMMT | |
|---|---|---|
Market Cap | $31.35B | $13.71B |
Volume | 1,337,978 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $385.50 | $26.38 |
52-Week Low | $192.49 | $12.43 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $33.63B | $13.04B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.16, down 0.1% with a bearish technical signal despite strong Q4 2026 earnings that beat expectations. The stock shows robust fundamentals with 74.11% ROE and positive earnings momentum, though current valuation metrics like P/E of 30.68 suggest premium pricing. Recent news highlights AI infrastructure demand driving 24% revenue growth projections for fiscal 2027.
JBL presents a compelling growth opportunity with strong AI-driven revenue projections and consistent earnings beats, though elevated valuation and bearish technical indicators warrant caution. The 35% upside to consensus price target of $434.75 offers potential reward, but investors should monitor execution risks in achieving aggressive growth targets amid market volatility.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
